Comparing two radiation therapies for node-positive breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of ultra-hypofractionated radiation therapy compared to standard hypofractionated radiation therapy in patients with node-positive breast cancer. The study aims to determine if the ultra-hypofractionated approach, which delivers a higher dose over fewer sessions, can provide similar oncologic outcomes while potentially improving quality of life and reducing treatment time. Participants will receive either treatment after undergoing surgery for their breast cancer, with careful monitoring of their health outcomes. The trial is designed to contribute to the evolving standards of care in breast cancer treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed invasive carcinoma of the breast. Metaplastic breast cancer is allowed.
* AJCC 8th Edition Stage: cT1-3 primary tumor. cN1-2 or pN1-2.
* Biopsy-proven involved axillary node(s) (either at baseline and/or at time of surgery).
* Undergone either partial mastectomy (with negative final histologic margins (defined as no tumor on ink, after initial surgery or re-excision)) or mastectomy (with negative histologic margins defined as tumor (either invasive or in situ disease) \> 2 mm from the final margin).
* Nodal surgery with either sentinel lymph node biopsy or axillary lymph node dissection. Effort to recover the original biopsy-proven node should be performed at time of surgery.
* Systemic therapy (chemotherapy and/or endocrine therapy) should be administered as per standard of care and recommendation of medical oncology. Neoadjuvant and/or adjuvant systemic therapy is allowed. Concurrent endocrine therapy, anti-HER2 therapy, and immunotherapy during RT is allowed.
* All radiation therapy must be planned to be delivered at BJH or a Siteman satellite location.
* Female.
* Age ≥ 18 years at diagnosis.
* ECOG Zubrod performance status 0 or 1.
* English speaker.
* Able to understand and willing to sign IRB-approved written informed consent document.

Exclusion Criteria:

* Presence of distant metastases.
* Diagnosis of nonepithelial breast malignancies such as sarcoma or lymphoma.
* Diagnosis of bilateral breast cancer.
* AJCC cT4 disease, pT4 disease, or any skin involvement on exam or pathology, including dermal LVSI.
* Presence of palpable or radiographically suspicious supraclavicular, infraclavicular, or internal mammary nodes.
* Prior radiation therapy which would have any overlap with current radiation therapy plan.
* Diagnosis of prior breast cancer or diagnosis of current breast cancer more than one year prior to enrollment.
* Diagnosis of systemic lupus erythematosis, scleroderma, or dermatomyositis.
* Diagnosis of a coexisting medical condition which limits life expectancy to \< 2 years.
* Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational treatment. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
* Time between last breast cancer surgery to RT simulation is greater than 10 weeks, or time between completion of chemotherapy to RT simulation is greater than 8 weeks, whichever is performed last prior to RT.
* Planning to undergo concurrent chemotherapy.
* Pregnancy, which will be excluded prior to simulation.

Where it's running

• Washington University School of Medicine
  St Louis, Missouri, United States Recruiting

Study contacts

• Principal investigator: Maria Thomas, M.D., Ph.D. — Washington University School of Medicine
• Study coordinator: Maria Thomas, M.D., Ph.D.
• Email: mariathomas@wustl.edu
• Phone: 314-362-8615

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preoperative chemotherapy with pembrolizumab and a low or high radiation boost for node-positive triple-negative breast cancer

  This study tests whether giving a low or high radiation boost together with preoperative chemotherapy and pembrolizumab can better activate the immune system in people with node‑positive triple‑negative breast cancer.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07276880

• Targeted sentinel node biopsy for breast cancer patients with limited axillary nodal disease

  This audit will test if removing the marked node along with the sentinel nodes can identify people with only 1–2 positive axillary nodes so some can avoid a full axillary dissection, for adults with cT1-2 breast cancer and biopsy-proven axillary metastases with no more than two abnormal nodes on imaging.

  Recruiting at 14 sites University Hospitals of Derby and Burton NHS Foundation Trust · Burnley and 13 other locations · NCT07085442

• Screening for metastasis in node-positive breast cancer after treatment

  This study is testing how often breast cancer spreads to other parts of the body in patients who have had chemotherapy and surgery, by using CT scans to check for any signs of metastasis.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06833502

• Using 68Ga-FAPi-46 PET/CT to study breast cancer

  This study is testing a new imaging method using a special agent to see if it can help women with node-positive breast cancer get better information about their tumors before starting treatment.

  Recruiting European Institute of Oncology · Milan, Italy · NCT06790264

• Evaluating targeted axillary dissection in breast cancer with multiple suspicious lymph nodes

  This study is testing if a less invasive surgery called targeted axillary dissection can safely help patients with breast cancer who have multiple suspicious lymph nodes after they receive initial treatment.

  Recruiting Kliniken Essen-Mitte · Essen · NCT05462457

• Ovarian function suppression for premenopausal women with low-risk breast cancer

  This study is testing if lowering ovarian function with hormone treatments can help premenopausal women with low-risk breast cancer after surgery feel better and avoid chemotherapy.

  Recruiting Phase 4 Gangnam Severance Hospital · Seoul, Korea and 1 other locations · NCT05333328

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.